Valeant Plans Sales Rep Increase, DTC Campaign For Jublia
This article was originally published in The Pink Sheet Daily
Valeant has something to prove with the launch of Jublia, a topical treatment for toenail fungus, which it has held up as an example of its R&D strategy at work.
You may also be interested in...
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.